Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 35
Summary
- Conditions
- Breast Cancer
- Breast Carcinoma
- Cancer of Breast
- Malignant Tumor of Breast
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Only males
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03007979
- Collaborators
- Pfizer
- Investigators
- Principal Investigator: Cynthia X Ma, M.D., Ph.D. Washington University School of Medicine